SCHEMBL5455735

SCHEMBL5455735

CCOc1ccc(C)cc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ccccc3C)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.50
KMT2A Q03164 5/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 3/20 0.50
HTT P42858 2/20 0.50
TP53 P04637 2/20 0.50
RAB9A P51151 1/20 0.50
HRH3 Q9Y5N1 1/20 0.49
P2RY12 Q9H244 1/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 1/20 0.47
BLM P54132 1/20 0.47
NPC1 O15118 1/20 0.46
GLA P06280 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
P2RX7 Q99572 1/20 0.46
GAA P10253 2/20 0.46
RBP4 P02753 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457912 0.92 KMT2A (0.55) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5462591 0.91 MAPT (0.49) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5455975 0.90 MAPT (0.58) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5465500 0.88 MAPT (0.47) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5460951 0.87 MAPT (0.53) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5465994 0.86 MAPT (0.56) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5458258 0.82 MAPT (0.53) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5464801 0.81 MAPT (0.68) MAPTKMT2ALMNASMN1; SMN2MEN1
SCHEMBL5460134 0.81 RBP4 (0.72) MAPTKMT2ALMNAMEN1TP53
SCHEMBL5455945 0.81 MAPT (0.57) MAPTKMT2ALMNASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885KMT2A 1350/4885LMNA 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.